Sign In
Buy CHRS
$1.46
-0.0200 (-1.35%)
At Close: Jun 23, 2026
Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update
04:15pm, Monday, 12'th May 2025
– Strategic transformation to innovative oncology completed in Q2 2025 – – Positive CHS-114 (anti-CCR8 antibody) Phase 1b dose expansion study data in patients with head and neck cancer presente
Coherus to Report First Quarter 2025 Financial Results on May 12, 2025
04:01pm, Monday, 05'th May 2025
REDWOOD CITY, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its first quarter 2025 financial results will be released after mar
Coherus to Participate in Upcoming Investor Conferences
05:04pm, Thursday, 01'st May 2025
REDWOOD CITY, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that the company will be webcasting its participation in the upcoming co
– CHS-114 demonstrates clinical efficacy and proof of mechanism in HNSCC in combination with toripalimab – – Confirmed partial response in heavily pretreated PD-1 refractory patient supports exp
Coherus BioSciences: Cleaning The Balance Sheet And Developing New Drugs
05:53am, Thursday, 17'th Apr 2025
Coherus BioSciences is now heavily focused on developing its pipeline, particularly casdozokitug and CHS-114, after shedding its marketed biosimilar drugs. Casdozokitug shows promise in metastatic hep
Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® Franchise
08:00am, Monday, 14'th Apr 2025
– $250 million post-close cash balance extends cash runway over two years into 2027, funding pipeline development through key data catalysts –
REDWOOD CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS), a commercial-stage innovative oncology company, today announced that an abstract high
Coherus BioSciences, Inc. (CHRS) Q4 2024 Earnings Call Transcript
08:52pm, Monday, 10'th Mar 2025
Coherus BioSciences, Inc. (NASDAQ:CHRS ) Q4 2024 Earnings Conference Call March 10, 2025 5:00 PM ET Company Participants Jodi Sievers - Head of IR Denny Lanfear - CEO Paul Reider - CCO Sameer Goregaok
Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update
04:12pm, Monday, 10'th Mar 2025
– Annual net revenue increased 4% to $267.0 million in 2024, despite significant divestitures – – UDENYCA® net revenue increased 62% year-over-year – – LOQTORZI® net revenue increased 29
Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025
08:30am, Monday, 03'rd Mar 2025
REDWOOD CITY, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its fourth quarter and full year 2024 financial results will be r
Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference
09:08am, Monday, 24'th Feb 2025
REDWOOD CITY, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that senior management will participate in a fireside chat presentation
Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025
08:30am, Wednesday, 18'th Dec 2024
- Randomized Phase 2 study initiated evaluating the combination of casdozokitug, toripalimab and bevacizumab in patients with liver cancer -
Coherus BioSciences: Shedding Pegfilgrastim To Fuel Ongoing Development
06:08pm, Monday, 16'th Dec 2024
Coherus BioSciences focuses on immunotherapy, expanding their PD-1 antibody market, and developing novel treatments for solid tumors, despite maintaining a penny stock valuation. Financially, CHRS hol
Why Is Coherus BioSciences Stock Trading Higher On Tuesday?
09:34am, Tuesday, 03'rd Dec 2024
On Tuesday, Coherus BioSciences, Inc. CHRS entered into an asset purchase agreement with Intas Pharmaceuticals Ltd for the divestiture of the Udenyca (pegfilgrastim-cbqv) franchise for up to $558.4
Coherus Management to Participate in the 2024 Citi Global Healthcare Conference
04:01pm, Wednesday, 27'th Nov 2024
REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that senior management will participate in the 2024 Citi Global Healthc
